SYGNIS strengthens patent position on AX200 for the treatment of neurodegenerative diseases

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Licensing Agreements

Heidelberg (euro adhoc) - SYGNIS strengthens patent position on AX200 for the treatment of neurodegenerative diseases

Heidelberg,  09  February  2011  -  SYGNIS  Pharma  AG  (Frankfurt:   LIOK;  ISIN DE000A1E9B74; Prime Standard),  a  clinical  stage   biotech  company  developing innovative therapies for the  treatment of  neurodegenerative  diseases,  today announced that it has licensed the exclusive rights to a European patent,  which will significantly expand SYGNIS´ IP-position with regard to its lead   candidate AX200. AX200, which is known as the G-CSF protein, is currently  in  a  clinical phase II efficacy trial for the treatment of acute ischemic stroke (AXIS 2).

The licence covers an issued patent which provides broad protection with  regard to the use of  G-CSF  for  the  reorganisation  of   neural  tissue  affected  by neurodegenerative diseases, especially   stroke  or  trauma.  The  patent  rights strengthen SYGNIS´ IP-position around AX200 in  the  current  AXIS  2-trial  and also cover the use  of  G-CSF  for  the  treatment  of  patients  in  the early rehabilitation-phase following a stroke. The patent has a scheduled expiry  date of  2022,  not  including  any  potential   extensions.  In  this    respect,    it complements the patent, granted in Europe in  2006  and  in  the  USA  in  2009, covering  the  use   of  AX200  for  the  treatment  of  stroke  by    stimulating arteriogenesis, to which SYGNIS has exclusive access under a  license agreement with the Max-Planck Gesellschaft.

Dr Frank Rathgeb, Chief  Medical  Officer  of  SYGNIS,  said:  "These exclusive patent rights  further  strengthen  the  significant   therapeutic  potential  of AX200. The current phase II efficacy trial for the treatment of  acute  ischemic stroke is progressing well and we expect to report  the  top-line  data  in  the second half of 2011. Our robust intellectual property position means we  are  in a strong position to maximise the market potential of AX200."

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,   is  a  specialty  pharmaceutical company listed on the Prime Standard of the German stock exchange.  The  Company is focused on the research and  development  of  innovative  therapies  for  the treatment of disorders of the Central Nervous System. SYGNIS´ core projects  are currently Acute Stroke for which SYGNIS´ lead clinical programme  is  AX200  as well as the preclinical KIBRA-project for the treatment of  different  forms  of dementia. All these disorders are  characterized  by  the  fact  that,  as  the disease progresses, nerve cells are damaged and die.  Although  there  is  great medical demand, there are currently no  or  only  inadequate  treatment   options available. SYGNIS´ strategy for growth includes the development of new  products from its own research and through in-licensing and acquisitions.

For further information please contact: SYGNIS Pharma AG: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812

Media-Contact: Julia Phillips Financial Dynamics Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this  press  release,   relating  neither  to  proven financial results nor other  historical data,  should  be  viewed  as  forward- looking, i.e. not definite. Such statements are  mainly  predictions  of  future results, trends, plans or goals. These statements should not  be  considered  to be total guarantees since given their very nature they are subject to known  and unknown risks and imponderability and can be affected  by other  factors  as  a consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG may deviate greatly from the   established  conclusions  or  implied  predictions contained in such statements. SYGNIS does not undertake to  publicly  update  or revise these statements in the light of new information  or  future  results or for any other reason.  ###

@@start.t2@@end of announcement                                                 euro adhoc

Contact: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812

Branche: Biotechnology
ISIN:      DE000A1E9B74
WKN:        A1E9B7
Index:    CDAX, Prime All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: